New target identified for Alzheimer’s disease

September 29, 2010

Neurological researchers at Rush University Medical Center have found a new therapeutic target that can potentially lead to a new way to prevent the progression of Alzheimer’s disease. The target called neutral sphingomyelinase (N-SMase) is a protein that when activated, can cause a chain of reactions in the cell leading to neuronal death and memory loss.

Results from the study funded by the National Institutes of Health and the Alzheimer’s Association will be published in the September 22 issue of the .

“There are multiple, neurotoxic, disease-causing pathways that converge on the neutral sphingomyelinase that can cause neuronal loss in the brain of an Alzheimer’s patient,” said Kalipada Pahan, PhD, neurological researcher and lead investigator at Rush. “If we can stop the activation of the neutral sphingomyelinase, we may be able to stop memory loss and the progression of Alzheimer’s disease.”

In the brain of a patient with Alzheimer’s disease, two abnormal structures called plaques and tangles are prime suspects in damaging and killing . While neurons die, other brain cells like astroglia and microglia do not die. These brain cells become activated, and the glial cell activation plays a key role in the destruction of neurons. However, the molecular mechanisms by which activated glial cells can kill neurons have been poorly understood until now.

Beta-amyloid, which is a protein fragment deposited in the brains of patients who have Alzheimer’s disease, causes the activation of glial cells. Neuritic plaques are mainly composed of aggregates of beta-amyloid. When healthy nerve cells in the brain are exposed to beta-amyloid, they exhibit a number of pathological changes that are characteristic of Alzheimer’s pathology.

Researchers at Rush were able to determine that the neutral sphingomyelinase is triggered by the activated brain cells and beta-amyloid. However, when the neutral sphingomyelinase was inhibited by using a small molecule inhibitor and a chemical inhibitor, the activated brain cells and beta amyloid were unable to kill neurons.

Experts tested the two inhibitors using human in a mouse model and a cell culture model.

“Understanding how the disease process works is important in identifying effective approaches to protect the brain and stop the progression of Alzheimer’s disease,” said Pahan. “The results of this study are very promising and our next step is to translate these findings to the clinic.”

“If we can develop and test a clinical medication that can target the neutral sphingomyelinase, we may be able to halt memory loss in Alzheimer's disease patients,” said Pahan.

Alzheimer's disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest tasks. In most people with Alzheimer's, symptoms first appear after age 60. Alzheimer's disease is the most common cause of dementia among older people. affects as many as 5.3 million Americans.

Related Stories

Recommended for you

Neuro chip records brain cell activity

October 26, 2016

Brain functions are controlled by millions of brain cells. However, in order to understand how the brain controls functions, such as simple reflexes or learning and memory, we must be able to record the activity of large ...

Can a brain-computer interface convert your thoughts to text?

October 25, 2016

Ever wonder what it would be like if a device could decode your thoughts into actual speech or written words? While this might enhance the capabilities of already existing speech interfaces with devices, it could be a potential ...

The current state of psychobiotics

October 25, 2016

Now that we know that gut bacteria can speak to the brain—in ways that affect our mood, our appetite, and even our circadian rhythms—the next challenge for scientists is to control this communication. The science of psychobiotics, ...

After blindness, the adult brain can learn to see again

October 25, 2016

More than 40 million people worldwide are blind, and many of them reach this condition after many years of slow and progressive retinal degeneration. The development of sophisticated prostheses or new light-responsive elements, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.